8-K: Femasys Files Prospectus for $9.8M ATM Offering

Femasys Inc. announced a prospectus supplement for an "at-the-market" offering of up to $9.8 million in common stock.

Summary

• Femasys Inc. filed a prospectus supplement on December 23, 2025, for the offer and sale of shares of its common stock.
• The aggregate offering price for the shares is up to $9,800,000.
• Sales will be conducted under an existing Equity Distribution Agreement, dated July 1, 2022, with Piper Sandler & Co. acting as the Sales Agent.
• Shares will be sold from time to time at the Company's sole discretion through an "at-the-market" offering method, as defined in Rule 415(a)(4) under the Securities Act of 1933.

Sentiment

Score: 5

Explanation: The filing is a procedural update for a capital raise. While it provides financial flexibility, it also introduces potential dilution for existing shareholders, balancing the sentiment to neutral.

Positives

• Provides Femasys Inc. with access to capital for general corporate purposes, offering financial flexibility.
• Utilizes an existing "at-the-market" facility, indicating a pre-planned and efficient capital raising mechanism.

Negatives

• Potential for dilution of existing shareholders as new common stock shares are offered and sold.

Risks

• The nature of an "at-the-market" offering carries the inherent risk of market price fluctuations impacting the actual proceeds received from the sale of shares.

Future Outlook

Femasys Inc. intends to offer and sell shares of its common stock from time to time, at its sole discretion, through its sales agent, under the existing Equity Distribution Agreement. This indicates a flexible, ongoing approach to potential capital raising.

Industry Context

At-the-market (ATM) offerings are a common and flexible capital-raising tool for publicly traded companies, particularly in the biotechnology or medical device sectors, allowing them to raise capital opportunistically without the need for a traditional underwritten offering. This method minimizes upfront costs and allows companies to tap into market demand as needed.

Comparison to Industry Standards

• This filing is a standard procedural update for an "at-the-market" equity offering, a common financing mechanism used across various industries, including life sciences.
• Many small to mid-cap companies, similar to Femasys, utilize ATM programs to maintain financial flexibility and fund ongoing operations, research and development, or commercialization efforts. No specific comparable companies, projects, or results are mentioned in the filing itself.

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings due to the issuance of new common stock.
• Company: Enhanced financial flexibility and access to capital to fund operations, research, and strategic initiatives.

Next Steps

• The Sales Agent (Piper Sandler & Co.) will use commercially reasonable efforts to sell the Shares from time to time, based upon instructions from Femasys Inc.

Key Dates

Recommendation

This filing is a procedural announcement regarding an "at-the-market" equity offering, which provides Femasys Inc. with capital-raising flexibility. While it addresses potential funding needs, it also introduces the possibility of shareholder dilution. Without additional operational or financial performance updates, a "hold" recommendation is appropriate as this filing alone does not fundamentally alter the investment thesis but rather outlines a financing mechanism. Investors should monitor the actual utilization of the ATM facility and its impact on the share count and cash position.

Keywords

Femasys Inc., FEMY, ATM offering, at-the-market, common stock, equity distribution agreement, capital raise, prospectus supplement, Piper Sandler & Co., SEC filing